NOK 2.05
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 1.00 NOK | -100.0% |
2022 | 2.91 Million NOK | 232.38% |
2021 | 877 Thousand NOK | 0.0% |
2020 | - NOK | 0.0% |
2019 | - NOK | 0.0% |
2018 | - NOK | -100.0% |
2017 | 421 Thousand NOK | 106.37% |
2016 | 204 Thousand NOK | 0.0% |
2015 | - NOK | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - NOK | 0.0% |
2024 Q1 | - NOK | -100.0% |
2023 Q3 | -199 Thousand NOK | 0.0% |
2023 FY | 1.00 NOK | -100.0% |
2023 Q2 | - NOK | -100.0% |
2023 Q4 | 1.00 NOK | 100.0% |
2023 Q1 | 1.65 Million NOK | -43.22% |
2022 Q3 | -2.18 Million NOK | 79.37% |
2022 Q2 | -10.61 Million NOK | 0.0% |
2022 FY | 2.91 Million NOK | 232.38% |
2022 Q1 | - NOK | -100.0% |
2022 Q4 | 2.91 Million NOK | 233.17% |
2021 Q2 | -570 Thousand NOK | 0.0% |
2021 FY | 877 Thousand NOK | 0.0% |
2021 Q1 | - NOK | 0.0% |
2021 Q4 | 1.63 Million NOK | 66.77% |
2021 Q3 | 981 Thousand NOK | 272.11% |
2020 Q4 | - NOK | 0.0% |
2020 Q3 | - NOK | 0.0% |
2020 Q2 | - NOK | 0.0% |
2020 FY | - NOK | 0.0% |
2020 Q1 | - NOK | 0.0% |
2019 Q2 | - NOK | 0.0% |
2019 Q4 | - NOK | 0.0% |
2019 FY | - NOK | 0.0% |
2019 Q3 | - NOK | 0.0% |
2018 Q3 | - NOK | 0.0% |
2018 Q1 | - NOK | 0.0% |
2018 FY | - NOK | -100.0% |
2018 Q2 | - NOK | 0.0% |
2018 Q4 | - NOK | 0.0% |
2017 FY | 421 Thousand NOK | 106.37% |
2017 Q4 | - NOK | 0.0% |
2016 FY | 204 Thousand NOK | 0.0% |
2015 FY | - NOK | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Arctic Bioscience AS | 32.79 Million NOK | 100.0% |
Aqua Bio Technology ASA | 5.69 Million NOK | 100.0% |
ArcticZymes Technologies ASA | 12.87 Million NOK | 100.0% |
BerGenBio ASA | 7.84 Million NOK | 100.0% |
Hofseth BioCare ASA | 82.54 Million NOK | 100.0% |
PCI Biotech Holding ASA | 1000.00 NOK | 99.9% |
Thor Medical ASA | - NOK | -Infinity% |